@MoffittNews Chair and Professor, Department of Radiation Oncology. Director, RO Cancer Health Disparities Research. Views are my own.
Joined October 2015
- Tweets 765
- Following 237
- Followers 983
- Likes 1,632
23 Photos and videos
Pinned Tweet
What an incredible day celebrating the ribbon-cutting at the @MoffittNews Speros Outpatient Center. I’m thrilled to showcase our Richard M. Schulze Family Foundation Proton Therapy Center, which will bring highly precise proton therapy to patients and expand access to care!
1
3
21
1,383
Kosj Yamoah MD, PhD retweeted
During the last morning poster session at #ASCO26, Kriti Gera, MD (@kriti_gera_), shares research comparing lymphodepletion strategies before CD19 CAR-T therapy, highlighting findings that suggest a potentially safer approach without compromising efficacy for patients with B-cell acute lymphoblastic leukemia. #MoffittASCO26
8
11
601
Kosj Yamoah MD, PhD retweeted
3
7
20
308,834
Kosj Yamoah MD, PhD retweeted
While at #ASCO26, Richard Kim, MD, stopped by the #MoffittASCO26 booth to discuss research exploring FGFR2-targeted treatment strategies, from real-world analyses in advanced cholangiocarcinoma to investigational approaches for patients with FGFR2-altered solid tumors, helping advance precision medicine in cancer care. #ASCO26
4
9
391
Kosj Yamoah MD, PhD retweeted
While at #ASCO26, Ariosto Silva, MD, shares research exploring an AI framework designed to bring together clinical, laboratory and molecular data to support personalized cancer care and accelerate future treatment discoveries. #MoffittASCO26
8
14
662
Kosj Yamoah MD, PhD retweeted
We caught up with Martine Extermann, MD, PhD, at the Moffitt booth during #ASCO26 to discuss advances in senior oncology research, including ways to help older adults better prepare for and recover from treatment while maintaining their quality of life. #MoffittASCO26
5
9
517
Kosj Yamoah MD, PhD retweeted
While at #ASCO26, Tiago Biachi, MD, PhD (@BiachiTiago), stopped by the booth to discuss research evaluating an investigational treatment approach for previously untreated, unresectable or metastatic colorectal cancer. #MoffittASCO26
11
18
883
Kosj Yamoah MD, PhD retweeted
During #ASCO26, Andrew Kuykendall, MD (@KuykendallMd), shares research exploring treatment patterns and overall survival in relapsed or refractory myelofibrosis, highlighting insights from clinical trial and real-world data. #MoffittASCO26
4
8
443
Kosj Yamoah MD, PhD retweeted
‼️New findings from the SARC041 trial presented at #ASCO26 suggest abemaciclib significantly improved progression-free survival in patients with advanced dedifferentiated liposarcoma, supporting its potential as a new treatment option for this rare sarcoma subtype.
Moffitt’s Mihaela Druta, MD (@MihaelaDruta), stopped by the booth to discuss the data from Mark Dickson, MD, of @MSKCancerCenter, highlighting the promise of a new therapy for patients with recurrent or metastatic dedifferentiated liposarcoma. #MoffittASCO26
8
24
1,297
Kosj Yamoah MD, PhD retweeted
At the final poster session at #ASCO26, Kamran Ahmed, MD (@KAhmedMD), shares research evaluating brain MRI surveillance in stage IV breast cancer and efforts to better understand brain metastases. #MoffittASCO26
1
8
23
850
Kosj Yamoah MD, PhD retweeted
At #ASCO26, Karen Lu, MD (@karenluMD), joins @PatrickHwuMD to discuss Moffitt’s strong presence at the annual meeting and the innovations driving the future of cancer care.
From advances in targeted therapies and immunotherapy to leadership in digital pathology and rare cancer diagnosis, they highlight how Moffitt continues to help shape the next generation of oncology breakthroughs. #MoffittASCO26
12
19
1,265
Kosj Yamoah MD, PhD retweeted
From #ASCO26, Mihaela Druta, MD (@MihaelaDruta), highlights a study she co-authored evaluating afamitresgene autoleucel (afami-cel), a MAGE-A4-targeted T-cell therapy, in advanced synovial sarcoma.
Pooled trial data showed meaningful responses, pointing to the potential of engineered T-cell therapies for patients with this rare and challenging disease. #MoffittASCO26
9
14
898
Kosj Yamoah MD, PhD retweeted
At #ASCO26, Mihaela Druta, MD (@MihaelaDruta), discusses one of her co-authored studies presented during the antibody-drug conjugate session evaluating mecbotamab vedotin, an AXL-targeting ADC, in heavily pretreated bone sarcomas.
Findings demonstrated encouraging overall survival outcomes, highlighting its potential in a patient population with significant unmet need. #MoffittASCO26
6
10
527
Kosj Yamoah MD, PhD retweeted
While at #ASCO26, Guilherme Rabinowits, MD, stopped by the #MoffittASCO26 booth to discuss findings from his research evaluating FID-007 in combination with cetuximab for recurrent or metastatic head and neck cancer, including encouraging response rates and a manageable safety profile. #ASCO26
4
10
546
Kosj Yamoah MD, PhD retweeted
From #ASCO26, Nikhil Khushalani, MD (@DrKhushalani), and Vernon Sondak, MD (@VernSondakMD), discuss emerging melanoma research that could help refine treatment strategies and improve quality of life for patients.
Highlights include new data on treatment de-escalation for patients with exceptional responses and next-generation TIL approaches designed to maintain efficacy while reducing treatment-related toxicity. #MoffittASCO26
1
7
11
692
Kosj Yamoah MD, PhD retweeted
While at #ASCO26, Zeynep Eroglu, MD, stopped by the booth to discuss research exploring adaptive treatment approaches in advanced BRAF V600E-mutant melanoma, using ctDNA, imaging and patient-specific treatment strategies to help guide therapy decisions. #MoffittASCO26
5
12
706
Kosj Yamoah MD, PhD retweeted
While at #ASCO26, Nikhil Khushalani, MD (@DrKhushalani), and Jonathan Zager, MD (@jzager99), discuss advances in uveal melanoma and surgical oncology research.
They highlight efforts to combine percutaneous hepatic perfusion with other therapies for metastatic uveal melanoma, as well as promising research from Moffitt fellows. #MoffittASCO26
8
18
793
Kosj Yamoah MD, PhD retweeted
From #ASCO26, Peter Forsyth, MD (@PeterForsyth27), and Muhammad Jaffer, MD, discuss advances in neuro-oncology, including long-term follow-up from the INDIGO trial showing durable benefits for patients with low-grade glioma and continued momentum toward earlier intervention.
They also highlight research focused on understanding and reducing neurologic toxicities associated with cancer therapies, with the goal of preserving quality of life while improving outcomes. #MoffittASCO26
5
10
803
Kosj Yamoah MD, PhD retweeted
While at #ASCO26, Nikhil Khushalani, MD (@DrKhushalani), and Zeynep Eroglu, MD, discuss promising advances in uveal melanoma, including a potentially practice-changing trial evaluating darovasertib in patients with HLA-A2-negative metastatic disease.
The study demonstrated a substantial improvement in progression-free survival and offers hope for a patient population with limited treatment options. #MoffittASCO26
8
19
969
Kosj Yamoah MD, PhD retweeted
From #ASCO26, Peter Forsyth, MD (@PeterForsyth27), and Brian Czerniecki, MD, PhD (@BCzernieckiMD), discuss the power of cross-disciplinary collaboration in advancing cancer care.
Their work combines expertise in neuro-oncology and immunotherapy to develop dendritic cell-based treatments for leptomeningeal disease in patients with breast cancer, with a phase 2 clinical trial now underway. #MoffittASCO26
11
22
899
Kosj Yamoah MD, PhD retweeted
At #ASCO26, Nikhil Khushalani, MD (@DrKhushalani), and Lilit Karapetyan, MD (@KarapetLilit), discuss advances in TIL therapy for melanoma.
Their conversation highlights research on the tumor microenvironment and collaborative efforts to better understand treatment-related toxicities, including cytopenias and infections, with the goal of optimizing patient selection and improving outcomes. #MoffittASCO26
10
18
1,029